Lixte Biotechnology Holdings
Biotechnology, 248 Rte 25a, East Setauket, New York, 11733, United States, 1-10 Employees
Who is LIXTE BIOTECHNOLOGY HOLDINGS
Lixte Biotechnology Holdings, Inc. (Lixte) is a clinical-stage public (LIXT) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has iden...
Read More
-
Headquarters: 248 Rte 25a, East Setauket, New York, 11733, United States
-
Date Founded: 2006
-
Employees: 1-10
-
Revenue: $1 Million to $5 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 621511 |
Show More
Does something look wrong? Fix it. | View contact records from LIXTE BIOTECHNOLOGY HOLDINGS
Lixte Biotechnology Holdings Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Lixte Biotechnology Holdings
Answer: Lixte Biotechnology Holdings's headquarters are located at 248 Rte 25a, East Setauket, New York, 11733, United States
Answer: Lixte Biotechnology Holdings's official website is https://lixte.com
Answer: Lixte Biotechnology Holdings's revenue is $1 Million to $5 Million
Answer: Lixte Biotechnology Holdings's SIC: 2834
Answer: Lixte Biotechnology Holdings's NAICS: 621511
Answer: Lixte Biotechnology Holdings has 1-10 employees
Answer: Lixte Biotechnology Holdings is in Biotechnology
Answer: Lixte Biotechnology Holdings contact info: Phone number: Website: https://lixte.com
Answer: Lixte Biotechnology Holdings, Inc. (Lixte) is a clinical-stage public (LIXT) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and DNA damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation. The phosphatase inhibitors enhance the effectiveness of cytotoxic anti-cancer drugs in general as well as radiation therapy making them potentially useful for the treatment of many, if not all, cancers in combination with existing standard chemotherapy regimens and the evolving targeted cytotoxic therapies of personalized cancer medicine. The lead compound LB-100 is in Phase I trial and has the potential to be first-in-class. The deacetylase inhibitors have anti-cancer activity and in model systems correct enzymes deficiencies underlying several inborn metabolic diseases including Gaucher and von Hippel-Lindau disease and neurofibromatosis type 2. Lixte's cancer drug development strategy has led to the discovery of novel compounds with the potential to be therapeutically useful against several other important but seemingly disparate diseases. The phosphatase inhibitors are in pre-clinical development for reducing the extent of tissue damage following stroke, heart attack, and septic shock; and, the deacetylase inhibitors for prevention and treatment of neurodegenerative diseases, traumatic brain injury, and topically for fungal dermatitis .
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month